Free Newsletter
Eli Lilly chief sees pay hike of 30%
Roll up your sleeves, folks. It's time once again to dig through the numbers on executive pay. First up: Eli Lilly chief John Lechleiter (photo). According to figures disclosed in a regulatory filing, Lechleiter scored a hefty raise in 2009. A really hefty raise, in fact: More than 30 percent.
Part of the jump between 2008 and 2009 came because Lechleiter took over as CEO partway through the previous year, and in 2009 he obviously served the entire 12 months in that post. Plus, the company's 2008 performance wasn't super-special, a spokesman tells the Associated Press, meaning Lechleiter got less incentive pay than he might have otherwise.
But enough of the explanations: You want the numbers. According to the proxy statement, Lechleiter's total package came in at $20.9 million. But the Associated Press and Wall Street Journal both come up with $16.4 million, because of various accounting rules that affect the proxy's reporting of the numbers. The company itself tells the IndyStar that the "real" number is more like $15.9 million.
We'll take the middle road and call it $16.4 million. According to Dow Jones, that total comprises $1.48 million in salary, $3.55 million in incentive pay, $11.25 million in equity, and $90,091 in tax reimbursements and savings-plan matching.
Don't expect another pay-increase story for Lechleiter next year; he's asked to forego any salary or bonus increase for 2010, given "the business challenges the company faces."
- see the IndyStar's piece
- get the WSJ Health Blog numbers
- check out the story from Dow Jones
- read the AP article
Related Articles:
Is Lilly CFO's promotion a succession plan?
Lilly's scientist CEO preps for 'Year Y'
Lilly chief: Megamergers 'driven by weakness'
Lilly execs pull down $48M
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: